Experimental Hematology
Volume 34, Issue 10 , Pages 1303-1311 , October 2006

Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia

Received 16 January 2006 ,Revised 15 May 2006 ,Accepted 16 May 2006.

References 

  1. Nissenson AR, Goodnough LT, Dubois RW. Anemia. Not just an innocent bystander?. Arch Intern Med. 2003;163:1400–1404
  2. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023
  3. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458–464
  4. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol. 1997 Nov;15:1261–1265.
  5. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev. 2003;2:214–221
  6. Knauf MJ, Bell DP, Hirtzer P, Luo Z, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem. 1998;263:15064–15070
  7. Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 2005;20:9–15
  8. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–475
  9. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood. 1993;82(2):456–464
  10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63
  11. Haseyama Y, Sawada K, Oda A, et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood. 1999;94:1568–1577
  12. Bouscary D, Pene F, Claessens Y, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood. 2003;101:3436–3443
  13. Richmond T, Chohan M, Barber D. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005;15:146–155
  14. Kawamura A, Higuchi M, Imai N, Kawaguchi T, Ogura Y. Effect of purified recombinant human erythropoietin on anemia in rats with experimental renal failure induced by five-sixth nephrectomy. Biotherapy. 1990;2:77–85
  15. Ni Z, Wang XQ, Vaziri ND. Nitric oxide metabolism in erythropoietin-induced hypertension. Effect of calcium channel blockade. Hypertension. 1998;32:724–729
  16. Bailon P, Spence C, Schaffer CA, et al. Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a. Antivir Ther. 1999;4:27
  17. Pepinsky RB, Doreen JL, Gil IA, et al. Improved pharmacokinetic properties of a polyethylene glycol–modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther. 2001;297:1059–1066
  18. Reddy KR, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev. 2002;54:571–586
  19. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290–299
  20. Moore DM. Hematology of nonhuman primates. Chapter 176. In:  Feldman BF,  Zinkl JG,  Jain NC editor. Schalm's Veterinary Hematology. 5th ed.. Philadelphia: Lippincott Williams & Wilkins; 2000;p. 1133–1144
  21. Moore DM. Hematology of the rat (Rattus norvegicus). Chapter 189. In:  Feldman BF,  Zinkl JG,  Jain NC editor. Schalm's Veterinary Hematology. 5th ed.. Philadelphia: Lippincott Williams & Wilkins; 2000;p. 1210–1224
  22. Stead RB, Lambert J, Wessels D, et al. Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates dose dependent activity and is well tolerated in a Phase 1 single dose, dose escalating study in Normal Healthy Volunteers (NHV). J Clin Oncol. 2005;23:16S, Abstract 773s

PII: S0301-472X(06)00329-8

doi: 10.1016/j.exphem.2006.05.012

Experimental Hematology
Volume 34, Issue 10 , Pages 1303-1311 , October 2006

Article Tools

* Image Usage & Resolution